xmlui.ArtifactBrowser.ConfigurableBrowse.title.metadata.authorArtikkelit"Kurki, Pekka"

2017 White Paper on recent issues in bioanalysis : A global perspective on immunogenicity guidelines & biomarker assay performance (Part 3-LBA: Immunogenicity, biomarkers and PK assays)

Gupta, S.; Richards, S.; Amaravadi, L.; Piccoli, S.; Desilva, B.; Pillutla, R.; Stevenson, L.; et.al.; Kurki, Pekka
Bioanalysis : 24 (Future Medicine, 2017)

The 2017 11th Workshop on Recent Issues in Bioanalysis took place in Los Angeles/Universal City, California, on 3-7 April 2017 with participation of close to 750 professionals from pharmaceutical/biopharmaceutical companies, ...

2017 White Paper on recent issues in bioanalysis: aren't BMV guidance/guidelines ‘Scientific’? : Part 1 – LCMS: small molecules, peptides and small molecule biomarkers

Welink, Jan; Yang, Eric; Hughes, Nicola; Rago, Brian; Woolf, Eric; Sydor, Jens; Coppola, Laura; et. al.; Kurki, Pekka
Bioanalysis : 22 (Future Science, 17.11.2017)

The 2017 11th Workshop on Recent Issues in Bioanalysis (11th WRIB) took place in Los Angeles/Universal City, California on 3–7 April 2017 with participation of close to 750 professionals from pharmaceutical/biopharmaceutical ...

2017 White Paper on recent issues in bioanalysis: rise of hybrid LBA/LCMS immunogenicity assays : Part 2: hybrid LBA/LCMS biotherapeutics, biomarkers & immunogenicity assays and regulatory agencies’ inputs

Neubert, Henrik; Song, AN; Lee, Anita; Wei, Cong; Duggan, Jeff; Keyang, Xu; et.al.; Kurki, Pekka
Bioanalysis : 23 (Future Science, 05.12.2017)

The 2017 11th Workshop on Recent Issues in Bioanalysis (11th WRIB) took place in Los Angeles/Universal City, California on 3–7 April 2017 with participation of close to 750 professionals from pharmaceutical/biopharmaceutical ...

2017 White Paper on recent issues in bioanalysis: rise of hybrid LBA/LCMS immunogenicity assays : Part 3 – LBA: immunogenicity, biomarkers and PK assays

Gupta, Shalini; Richards, Susan; Amaravadi, Lakshmi; Piccoli, Steven; Desilva, Binodh; Pillutla, Renuka; Stevenson, Lauren; et. al.; Kurki, Pekka
Bioanalysis : 9 (Future Science, 05.12.2017)

The 2017 11th Workshop on Recent Issues in Bioanalysis (11th WRIB) took place in Los Angeles/Universal City, California on 3–7 April 2017 with participation of close to 750 professionals from pharmaceutical/biopharmaceutical ...

Biosimilar regulation in the EU

Kurki, Pekka; Ekman, Niklas
Expert review of clinical pharmacology : 5 (Taylor & Francis, 2015)

ECCO position challenged by European drug regulators

Kurki, Pekka; Bielsky, M.C.
Journal of Crohn's & colitis : 3 (Elsevier, 14.02.2014)

EU Perspective on Biosimilars

Kurki, Pekka; Ekman, Niklas
AAPS Advances in the Pharmaceutical Sciences Series : 34 (Springer, 14.12.2018)

Immunogenicity Assessment of Biosimilars

Reinivuori, Tiina; Kurki, Pekka; Chamberlain, Paul T.
Pharmaceutical Medicine : 2 (Springer International Publishing, 06.04.2018)

Interchangeability of Biosimilars : A European Perspective

Kurki, Pekka; vanAerts, L.; Wolff-Holz, E.; Giezen, T.; Skibeli, V.; Weise, M.
BioDrugs : 2 (Springer International Publishing, 01.04.2017)

Many of the best-selling ‘blockbuster’ biological medicinal products are, or will soon be, facing competition from similar biological medicinal products (biosimilars) in the EU. Biosimilarity is based on the comparability ...

Is there any research evidence beyond surveys and opinion polls on automatic substitution of biological medicines? : A systematic review

Tolonen, Hanna M.; Falck, Jenni; Kurki, Pekka; Ruokoniemi, Päivi; Hämeen-Anttila, Katri; Shermock, Kenneth M.; Airaksinen, Marja
BioDrugs : 35 (Springer, 2021)

Medication safety risks to be managed in national implementation of automatic substitution of biological medicines : a qualitative study

Tolonen, Hanna M; Airaksinen, Marja SA; Ruokoniemi, Päivi; Hämeen-Anttila, Katri; Shermock, Kenneth M; Kurki, Pekka
BMJ Open : 9 (10 / 2019)

Artikkelit - Selaus tekijän mukaan "Kurki, Pekka"

2017 White Paper on recent issues in bioanalysis : A global perspective on immunogenicity guidelines & biomarker assay performance (Part 3-LBA: Immunogenicity, biomarkers and PK assays)

2017 White Paper on recent issues in bioanalysis: aren't BMV guidance/guidelines ‘Scientific’? : Part 1 – LCMS: small molecules, peptides and small molecule biomarkers

2017 White Paper on recent issues in bioanalysis: rise of hybrid LBA/LCMS immunogenicity assays : Part 2: hybrid LBA/LCMS biotherapeutics, biomarkers & immunogenicity assays and regulatory agencies’ inputs

2017 White Paper on recent issues in bioanalysis: rise of hybrid LBA/LCMS immunogenicity assays : Part 3 – LBA: immunogenicity, biomarkers and PK assays

Biosimilar regulation in the EU

ECCO position challenged by European drug regulators

EU Perspective on Biosimilars

Immunogenicity Assessment of Biosimilars

Interchangeability of Biosimilars : A European Perspective

Is there any research evidence beyond surveys and opinion polls on automatic substitution of biological medicines? : A systematic review

Medication safety risks to be managed in national implementation of automatic substitution of biological medicines : a qualitative study

Miksi biosimilaarit kannattaa ottaa käyttöön?

Miksi biosimilaarit kannattaa ottaa käyttöön?

Roundtable on biosimilars with European regulators and medical societies, Brussels, Belgium, 12 January 2016

Tehokas ja turvallinen insuliinihoito voi olla halvempaa

Artikkelit - Selaus tekijän mukaan "Kurki, Pekka"

2017 White Paper on recent issues in bioanalysis : A global perspective on immunogenicity guidelines & biomarker assay performance (Part 3-LBA: Immunogenicity, biomarkers and PK assays) ﻿

2017 White Paper on recent issues in bioanalysis: aren't BMV guidance/guidelines ‘Scientific’? : Part 1 – LCMS: small molecules, peptides and small molecule biomarkers ﻿

2017 White Paper on recent issues in bioanalysis: rise of hybrid LBA/LCMS immunogenicity assays : Part 2: hybrid LBA/LCMS biotherapeutics, biomarkers & immunogenicity assays and regulatory agencies’ inputs ﻿

2017 White Paper on recent issues in bioanalysis: rise of hybrid LBA/LCMS immunogenicity assays : Part 3 – LBA: immunogenicity, biomarkers and PK assays ﻿

Biosimilar regulation in the EU ﻿

ECCO position challenged by European drug regulators ﻿

EU Perspective on Biosimilars ﻿

Immunogenicity Assessment of Biosimilars ﻿

Interchangeability of Biosimilars : A European Perspective ﻿

Is there any research evidence beyond surveys and opinion polls on automatic substitution of biological medicines? : A systematic review ﻿

Medication safety risks to be managed in national implementation of automatic substitution of biological medicines : a qualitative study ﻿

Miksi biosimilaarit kannattaa ottaa käyttöön? ﻿

Miksi biosimilaarit kannattaa ottaa käyttöön? ﻿

Roundtable on biosimilars with European regulators and medical societies, Brussels, Belgium, 12 January 2016 ﻿

Tehokas ja turvallinen insuliinihoito voi olla halvempaa ﻿

2017 White Paper on recent issues in bioanalysis : A global perspective on immunogenicity guidelines & biomarker assay performance (Part 3-LBA: Immunogenicity, biomarkers and PK assays)

2017 White Paper on recent issues in bioanalysis: aren't BMV guidance/guidelines ‘Scientific’? : Part 1 – LCMS: small molecules, peptides and small molecule biomarkers

2017 White Paper on recent issues in bioanalysis: rise of hybrid LBA/LCMS immunogenicity assays : Part 2: hybrid LBA/LCMS biotherapeutics, biomarkers & immunogenicity assays and regulatory agencies’ inputs

2017 White Paper on recent issues in bioanalysis: rise of hybrid LBA/LCMS immunogenicity assays : Part 3 – LBA: immunogenicity, biomarkers and PK assays

Biosimilar regulation in the EU

ECCO position challenged by European drug regulators

EU Perspective on Biosimilars

Immunogenicity Assessment of Biosimilars

Interchangeability of Biosimilars : A European Perspective

Is there any research evidence beyond surveys and opinion polls on automatic substitution of biological medicines? : A systematic review

Medication safety risks to be managed in national implementation of automatic substitution of biological medicines : a qualitative study

Miksi biosimilaarit kannattaa ottaa käyttöön?

Miksi biosimilaarit kannattaa ottaa käyttöön?

Roundtable on biosimilars with European regulators and medical societies, Brussels, Belgium, 12 January 2016

Tehokas ja turvallinen insuliinihoito voi olla halvempaa